Bli medlem
Bli medlem

Du är här

2016-10-25

Herantis Pharma Oyj: Herantis Pharma plc and Renishaw plc sign collaboration agreement on Parkinson's study

Herantis Pharma plc and Renishaw plc sign collaboration agreement on
Parkinson's study

Herantis Pharma Plc
Company release 25 Oct 2016 at 9:00 am

Herantis Pharma plc ("Herantis") and Renishaw plc ("Renishaw") have signed a
collaboration agreement related to the first clinical study of CDNF in
Parkinson's disease. Under the agreement, the Drug Delivery System developed
by Renishaw will be used for the clinical administration of CDNF. Herantis
and Renishaw will jointly contribute to funding of the clinical study and
both companies expect to independently benefit from the clinical data on CDNF
and Drug Delivery System respectively.

"Collaboration with Renishaw is extremely valuable for us," saysSigrid Booms
, Herantis' Director for Clinical Research. "In addition to benefitting from
their novel and innovative technology in the clinical study we will also get
the expertise and resources of an experienced global company."

Herantis and Renishaw are also partners in a consortium currently preparing an
approximately €6 million grant agreement with the EU's Horizon 2020 framework
programme related to the clinical study. Clinical trial applications have
been submitted to regulatory authorities. Due to prolonged regulatory
processes and ongoing EU grant negotiations the study's planned launch of
patient recruitment has been postponed from end of 2016 to the first half of
2017.

Renishaw is a global company headquartered in the United Kingdom, with core
skills in measurement, motion control, healthcare, spectroscopy and
manufacturing. It develops innovative products that significantly advance its
customers' operational performance - from improving manufacturing
efficiencies and raising product quality, to maximizing research capabilities
and improving the efficacy of medical procedures.

The collaboration and schedule change do not impact the outlook or guidance of
Herantis.

Further information:

Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site:www.herantis.com

Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246

About Parkinson's disease

Parkinson's disease is a slowly progressing neurodegenerative disease caused
by the death of dopaminergic neurons in the brains. Common first symptoms of
the disease include tremors, rigidity and slowness of movement. While the
motor symptoms can be treated with medication the disease progression cannot
be prevented, and the benefits of medication may be lost with disease
progression or side effects can become unmanageable. In addition, Parkinson's
disease may cause non-motor symptoms such as sleep problems, depression, and
anxiety, which are not alleviated by current Parkinson's drugs. Estimated 7
million people worldwide have Parkinson's disease.

About CDNF

CDNF, or Cerebral Dopamine Neurotrophic Factor, is an endoplasmic reticulum
located and secreted protein with neuroprotective and neurorestorative
properties, patented worldwide by Herantis. Following a preclinical
development program, which has showed it as efficacious in several
preclinical models of Parkinson's disease (PD), Herantis is preparing for a
first-in-human clinical study of CDNF in the treatment of PD and has a
preclinical development program for the treatment of ALS.

In preclinical studies including chronic toxicology studies, CDNF
administration has been safe; CDNF has protected and regenerated midbrain
dopamine-generating cells suggesting a potential for disease modification of
PD; it has also shown efficacy in non-motor symptoms in PD. In an ALS disease
model CDNF has significantly increased survival and reduced symptoms. This
suggests the potential to address unmet clinical needs in both PD and ALS.
CDNF is based on research at the Institute of Biotechnology at the University
of Helsinki, lead by professor Mart Saarma.

About Herantis Pharma Plc

Herantis Pharma Plc is a drug development company focused on early clinical
development of innovative drugs in unmet clinical needs. Our special emphasis
is in regenerative medicine where the company has two first-in-class assets
based on globally leading science in their fields: CDNF for neurodegenerative
diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer
associated lymphedema, with potential also in primary lymphedema. The shares
of Herantis are listed on the First North Finland marketplace run by Nasdaq
Helsinki stock exchange.

Distribution:

Nasdaq Helsinki
Main media
www.herantis.com

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.